ANIP Stock Overview
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
ANI Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$29.82|
|52 Week High||US$60.23|
|52 Week Low||US$22.73|
|1 Month Change||-6.46%|
|3 Month Change||-18.19%|
|1 Year Change||-11.49%|
|3 Year Change||-56.13%|
|5 Year Change||-31.75%|
|Change since IPO||373.33%|
Recent News & Updates
ANI Pharmaceuticals (NASDAQ:ANIP) Is Making Moderate Use Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
|ANIP||US Pharmaceuticals||US Market|
Return vs Industry: ANIP underperformed the US Pharmaceuticals industry which returned 13.5% over the past year.
Return vs Market: ANIP exceeded the US Market which returned -13.2% over the past year.
|ANIP Average Weekly Movement||8.7%|
|Pharmaceuticals Industry Average Movement||11.7%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: ANIP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ANIP's weekly volatility (9%) has been stable over the past year.
About the Company
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.
ANI Pharmaceuticals Fundamentals Summary
|ANIP fundamental statistics|
Is ANIP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ANIP income statement (TTM)|
|Cost of Revenue||US$113.00m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.91|
|Net Profit Margin||-28.05%|
How did ANIP perform over the long term?See historical performance and comparison
Is ANI Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ANIP ($29.82) is trading below our estimate of fair value ($175.63)
Significantly Below Fair Value: ANIP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ANIP is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Pharmaceuticals industry average.
PE vs Market: ANIP is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ANIP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ANIP is good value based on its Price-To-Book Ratio (1.5x) compared to the US Pharmaceuticals industry average (1.7x).
How is ANI Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ANIP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: ANIP is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ANIP's is expected to become profitable in the next 3 years.
Revenue vs Market: ANIP's revenue (11.7% per year) is forecast to grow faster than the US market (7.7% per year).
High Growth Revenue: ANIP's revenue (11.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ANIP's Return on Equity is forecast to be high in 3 years time
How has ANI Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ANIP is currently unprofitable.
Growing Profit Margin: ANIP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ANIP is unprofitable, and losses have increased over the past 5 years at a rate of 65.9% per year.
Accelerating Growth: Unable to compare ANIP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANIP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.9%).
Return on Equity
High ROE: ANIP has a negative Return on Equity (-18.15%), as it is currently unprofitable.
How is ANI Pharmaceuticals's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ANIP's short term assets ($301.4M) exceed its short term liabilities ($79.5M).
Long Term Liabilities: ANIP's short term assets ($301.4M) do not cover its long term liabilities ($319.2M).
Debt to Equity History and Analysis
Debt Level: ANIP's net debt to equity ratio (60.7%) is considered high.
Reducing Debt: ANIP's debt to equity ratio has reduced from 88.5% to 83% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ANIP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ANIP has less than a year of cash runway if free cash flow continues to grow at historical rates of 31.1% each year.
What is ANI Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ANIP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ANIP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ANIP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ANIP's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ANIP has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nikhil Lalwani (43 yo)
Mr. Nikhil Lalwani served as a Director of Association for Accessible Medicines. He served as the Chief Executive Officer of InvaGen Pharmaceuticals, Inc. since October 24, 2016. Mr. Lalwani is a seasoned...
CEO Compensation Analysis
Compensation vs Market: Nikhil's total compensation ($USD6.54M) is above average for companies of similar size in the US market ($USD2.69M).
Compensation vs Earnings: Nikhil's compensation has increased whilst the company is unprofitable.
Experienced Management: ANIP's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: ANIP's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ANIP insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.1%.
ANI Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: ANI Pharmaceuticals, Inc.
- Ticker: ANIP
- Exchange: NasdaqGM
- Founded: 2001
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$483.978m
- Shares outstanding: 16.23m
- Website: https://www.anipharmaceuticals.com
Number of Employees
- ANI Pharmaceuticals, Inc.
- 210 Main Street West
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/25 00:00|
|End of Day Share Price||2022/05/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.